Loading company…
Develops engineered endolysins for chronic dermatological and oncological conditions.
Micreos develops engineered endolysins, proteins intended to target pathogens such as Staphylococcus aureus while preserving beneficial microbiota. Its work focuses on conditions including atopic dermatitis and cutaneous T-cell lymphoma. Founded in 2005, the company is based in The Hague, Netherlands. In October 2022, it raised EUR 25 million in growth funding.
Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.
Sign in